401. Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer.
- Author
-
Saito A, Kitayama J, Horie H, Koinuma K, Kawashima R, Ohzawa H, Yamaguchi H, Kawahira H, Mimura T, Lefor AK, and Sata N
- Subjects
- Humans, Retrospective Studies, CD8-Positive T-Lymphocytes, Hypoglycemic Agents adverse effects, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Tumor Microenvironment, Diabetes Mellitus, Type 2 complications, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Colorectal Neoplasms drug therapy
- Abstract
Dipeptidyl peptidase IV inhibitor (DPP-4i) has been shown to act either as a promoter or as a suppressor for cancer. Although epidemiologic studies suggest that DPP-4i does not correlate with the development of malignancies, its effects on cancer metastases are controversial. We evaluated the impact of DPP-4i on postoperative outcomes of the diabetic patients with colorectal cancer and microscopic features of the resected tumors. In 260 consecutive patients with type 2 diabetes mellitus (T2DM) who underwent curative resection of colorectal cancer, the correlation between DPP-4i use and prognosis was retrospectively examined. Expression of Zeb1 on tumor cells and density of infiltrating immune cells were quantitatively evaluated with multicolor IHC in 40 tumors from DPP-4i users, 40 tumors from propensity score-matched users, and 40 tumors from nonusers. Postoperative disease-free survival (DFS) was significantly lower in 135 patients treated with DPP-4i compared with 125 nontreated patients [5-year DFS, 73.7% vs. 87.4%; HR, 1.98; 95% confidence interval (CI), 1.05-3.71; P = 0.035]. IHC revealed that the number of Zeb1
+ tumor cells increased in tumors from DPP-4i-treated patients than tumors from nonusers ( P < 0.01). The densities of CD3+ and CD8+ T cells were significantly lower in tumors from DPP-4i users ( P < 0.01) with decreased density of tertiary lymphoid structures ( P < 0.001). However, the density of M2-type tumor-associated macrophages with CD68+ CD163+ phenotypes was significantly higher ( P < 0.01) in tumors from DPP-4i users. Exposure of colorectal cancer to DPP-4i may accelerate epithelial-to-mesenchymal transition (EMT) creating a tumor-permissive immune microenvironment, which might impair the outcomes of the patients with colorectal cancer and T2DM., Significance: DPP-4i has been shown to enhance the antitumor effects of immunotherapy. However, we found that DPP-4i significantly impairs the outcomes of patients with colorectal cancer who underwent curative resection, possibly through acceleration of EMT and creation of a tumor-permissive immune microenvironment. This suggests that DPP-4i must be used with caution until its safety is fully confirmed by further studies of the mechanistic effects on existing cancers in humans., Competing Interests: H. Yamaguchi reports grants from Taiho Pharmaceutical, Co., Ltd, Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., and grants from ONO Pharmaceutical Co., Ltd. outside the submitted work. No other disclosures were reported., (© 2021 The Authors; Published by the American Association for Cancer Research.)- Published
- 2021
- Full Text
- View/download PDF